High BNP and NT-proBNP:
what they mean in heart failure

Article written and reviewed by Dr Luca Moretti

BNP and NT-proBNP are blood tests widely used when heart failure is suspected. A high value indicates that the heart is under greater hemodynamic stress and makes heart failure more likely, but does not by itself establish a diagnosis. Age, heart rhythm, kidney function, body weight, and numerous other conditions can affect the result.
The 2026 ESC guidelines introduced age-specific outpatient thresholds for NT-proBNP because a single cutoff tends to produce many false-positive results in older people.

In practical terms, it is important to remember that:

• BNP and NT-proBNP are biomarkers of cardiac wall stress;
• low values are particularly useful for making heart failure less likely;
• elevated values should be interpreted together with symptoms, clinical examination, and echocardiography;
• NT-proBNP rises physiologically with age and may be higher in kidney disease and atrial fibrillation;
• obesity can result in values lower than expected;
• the thresholds used in the outpatient setting differ from those used in patients with acute dyspnea or decompensated heart failure.

These tests are part of the pathway described in the guide on how heart failure is diagnosed. The result should therefore not be interpreted in isolation or compared with a generic threshold found online without taking age and the clinical situation into account.

What BNP and NT-proBNP are

When the walls of the heart are subjected to greater tension, cardiomyocytes release natriuretic peptide precursors. ProBNP gives rise to BNP, which is biologically active, and NT-proBNP, an inactive fragment that is nevertheless very useful as a biomarker. Both reflect, with different characteristics, the stress associated with intracardiac pressure and volume.
For this reason, they can increase in heart failure, both with reduced ejection fraction and with preserved ejection fraction. However, they do not indicate the cause of heart failure and cannot by themselves establish whether the problem is due to ischemia, valvular disease, cardiomyopathy, or another disorder.

BNP and NT-proBNP are not numerically interchangeable. They have different half-lives and elimination pathways and are measured with different assays. Treatment can also affect them differently: neprilysin inhibitors, such as sacubitril/valsartan, can alter BNP because they interfere with its degradation, whereas NT-proBNP is not a direct substrate of neprilysin and is often preferred during follow-up in these patients.

NT-proBNP and BNP values when chronic heart failure is suspected

In a patient evaluated in the outpatient setting for suspected heart failure, the 2026 ESC guidelines propose age-related NT-proBNP thresholds above which the diagnosis becomes more likely:

• NT-proBNP ≥125 pg/mL below age 50;
• NT-proBNP ≥250 pg/mL between ages 50 and 75;
• NT-proBNP ≥500 pg/mL above age 75.

For BNP, a value of 35 pg/mL is used in the outpatient diagnostic pathway; at present there are insufficient data to define age-specific BNP thresholds. These numbers should not be read as an absolute boundary between "healthy" and "diseased": they help determine how plausible heart failure is and how strongly prompt echocardiography and specialist assessment are indicated.
A result below the thresholds makes the diagnosis less likely, but if clinical suspicion remains high the assessment may still continue, particularly in conditions in which natriuretic peptides can be falsely low.

Values used when the patient has acute dyspnea

Different thresholds are used in the emergency department or when decompensated heart failure is suspected. The 2026 ESC guidelines retain age-independent rule-out values of NT-proBNP <300 pg/mL or BNP <100 pg/mL. Lower values make it less likely that acute dyspnea is due to heart failure, although they do not replace clinical assessment.
To improve diagnostic specificity, NT-proBNP can also be interpreted using age-related thresholds above which decompensated heart failure is considered more likely: above 450 pg/mL below age 50, above 900 pg/mL between ages 50 and 74, and above 1800 pg/mL above age 74.

The 2026 ESC guidelines also indicate that an NT-proBNP above 5000 pg/mL in the setting of decompensated heart failure identifies a very high-risk profile, and hospitalization is generally recommended. This information concerns the clinical assessment of an acutely ill patient and should not be used by the patient as an isolated criterion for deciding independently whether or not to go to the hospital.
In the presence of severe breathing difficulty, chest pain, fainting, or other emergency warning signs, the decision should be based first and foremost on symptoms and clinical stability, not on waiting for a laboratory test.

Why BNP or NT-proBNP can be high without heart failure

Natriuretic peptides rise with cardiac stress, not exclusively with heart failure. Elevated values can be seen with atrial fibrillation, advanced age, impaired kidney function, acute coronary syndromes, pulmonary hypertension, valvular heart disease, ventricular hypertrophy, pulmonary embolism, myocarditis, severe anemia, major infections, and other conditions.
For this reason, a report showing "high NT-proBNP" does not automatically mean that the patient has heart failure. The higher the value, the more the probability of the diagnosis increases in the appropriate clinical context, but objective confirmation must still be sought.

The opposite problem also exists: relatively low values do not always exclude the disease. Obesity is associated with lower natriuretic peptide concentrations, and some patients with heart failure with preserved ejection fraction may have values that are less elevated than expected. Several effective heart failure treatments also tend to reduce cardiac stress over time and therefore lower biomarker levels.

How to interpret the result correctly

The most appropriate way to interpret BNP or NT-proBNP is to regard them as one part of the diagnostic pathway. The doctor assesses why the test was requested, whether the patient is stable or has acute dyspnea, age, weight, kidney function, heart rhythm, and current treatments. The result is then integrated with ECG, chest X-ray, and, above all, echocardiography.
If a value is elevated, echocardiography is used to look for structural and functional abnormalities, estimate ejection fraction, and assess the valves, cardiac chambers, and filling pressures. If the value is low but suspicion remains high, the presence of obesity, HFpEF, or other conditions may still justify further investigations.

In patients with known heart failure, BNP and NT-proBNP also have prognostic value, but changes over time must be interpreted cautiously. Patients should not independently change treatment or the dose of a diuretic on the basis of a single result: clinical course, congestion, blood pressure, kidney function, electrolytes, and the overall treatment plan all matter.

Frequently asked questions about BNP and NT-proBNP

Does a high BNP always mean heart failure?
No. An elevated value increases the likelihood of heart failure in the appropriate context, but it can also increase with advanced age, atrial fibrillation, kidney disease, valvular heart disease, pulmonary hypertension, acute coronary syndromes, severe anemia, and other conditions.

What NT-proBNP values are used in the 2026 ESC guidelines in the outpatient setting?
The 2026 ESC guidelines indicate that heart failure is more likely above levels of at least 125 pg/mL below age 50, at least 250 pg/mL between ages 50 and 75, and at least 500 pg/mL above age 75. Values must still be interpreted in the clinical context.

What BNP value is used when chronic heart failure is suspected?
For BNP, a value of 35 pg/mL is used as a reference in the outpatient diagnostic pathway; the 2026 ESC guidelines do not currently propose age-specific BNP thresholds.

Does a low NT-proBNP always rule out heart failure?
No. Low values make heart failure less likely, but they can be falsely reassuring in some situations, particularly in obesity and in some patients with heart failure with preserved ejection fraction. If clinical suspicion remains high, echocardiography may still be necessary.

Are BNP and NT-proBNP the same thing?
They are two molecules derived from the same precursor and are both used as biomarkers of cardiac stress. However, they have different biological characteristics and thresholds, and their values should not be compared as though they were equivalent.